They do have other potential blockbusters in the pipeline such as Garadacimab (CSL312), a novel, fully-human monoclonal antibody that inhibits activated factor XII (FXIIa), for the prevention of hereditary angioedema attacks. Phase III trials complete. Forecast to add $50 to share price
CSL112, page-4
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$277.90 |
Change
-2.100(0.75%) |
Mkt cap ! $134.2B | |||
| Open | High | Low | Value | Volume |
| $280.53 | $281.98 | $277.90 | $117.0M | 419.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1009 | $277.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $278.06 | 399 | 2 |
View Market Depth
| Last trade - 16.10pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$278.55 |
Change
-2.100 ( 0.48 %) |
||||
| Open | High | Low | Volume | ||
| $281.64 | $281.94 | $278.33 | 24412 | ||
| Last updated 15.59pm 20/05/2024 ? | |||||
| CSL (ASX) Chart |